Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Top-line data from the double-blind, U.S. Phase IIa TIME-2 trial in 144 patients showed that twice-daily 15 mg subcutaneous AKB-9778
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury